Helsinn, Dr Reddy’s settle patent dispute

Swiss Pharma firm Helsinn reaches settlement agreement with Dr Reddy's regarding patent dispute on ALOXI

law-40007-640

Dr Reddy's will be permitted to market a generic version of Aloxi in the United States

Helsinn Healthcare SA announces that it has entered into a settlement agreement with Dr Reddy's Laboratories to resolve certain patent litigations relating to Helsinn Healthcare's Aloxi (palonosetron HCl injection) in the United States, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai.

As a result of the settlement, Dr Reddy's will be permitted to market a 505(j) generic version of Aloxi in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X